Form 8-K - Current report:
SEC Accession No. 0001140361-25-020713
Filing Date
2025-05-29
Accepted
2025-05-29 07:33:23
Documents
13
Period of Report
2025-05-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20049462_8k.htm   iXBRL 8-K 26630
2 EXHIBIT 99.1 ef20049462_ex99-1.htm EX-99.1 301369
  Complete submission text file 0001140361-25-020713.txt   477269

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA roiv-20250529.xsd EX-101.SCH 3979
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20250529_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20250529_pre.xml EX-101.PRE 16042
15 EXTRACTED XBRL INSTANCE DOCUMENT ef20049462_8k_htm.xml XML 4208
Mailing Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB
Business Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 25997704
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)